MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$43,423,000
EPS
-$0.39
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2025-12-31
2025-09-30
Product revenue, net
-
0
0
Cost of sales
-
0*
0
Cost of sales - inventory impairment and loss on firm purchase commitments
-
0*
0
Acquired in-process research and development
-
0*
0
Research and development
23,768,000
21,213,000
19,855,000
Selling, general and administrative
21,925,000
15,391,000
16,172,000
Restructuring expenses
-
0*
0
Total operating expenses
45,693,000
36,604,000
36,027,000
Loss from operations
-45,693,000
-36,604,000
-36,027,000
Interest income
2,323,000
3,290,000
1,821,000
Other expense, net
-53,000
361,000
-180,000
Total other income, net
2,270,000
3,651,000
1,641,000
Loss before income taxes
-43,423,000
-32,953,000
-34,386,000
Provision (benefit) for income taxes
-
46,000
0
Net loss
-43,423,000
-32,999,000
-34,386,000
Basic EPS
-0.39
-0.3
-0.37
Diluted EPS
-0.39
-0.3
-0.37
Basic Average Shares
111,196,883
110,093,662
93,332,930
Diluted Average Shares
111,196,883
110,093,662
93,332,930
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$43,423,000
(-4.78%↓ Y/Y)
Interest income
$2,323,000
(18.52%↑ Y/Y)
Loss before income
taxes
-$43,423,000
(-4.78%↓ Y/Y)
Total other income,
net
$2,270,000
(60.54%↑ Y/Y)
Other expense, net
-$53,000
(90.29%↑ Y/Y)
Loss from operations
-$45,693,000
(-6.62%↓ Y/Y)
Total operating
expenses
$45,693,000
(6.62%↑ Y/Y)
Research and development
$23,768,000
(-12.67%↓ Y/Y)
Selling, general and
administrative
$21,925,000
(40.19%↑ Y/Y)
Buy us a coffee
Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (AMLX)